Rivaroxaban May Increase Platelet Activation In Vivo via Thromboxane A2.
作者： Philip T. Murphy , Sarah Grace , Siobhan Glavey , John Quinn
DOI: 10.1161/CIRCRESAHA.119.315453
关键词: Platelet activation 、 Pharmacology 、 Rivaroxaban 、 Platelet aggregation 、 Thromboxane A2 、 Cerebellum 、 Medicine 、 In vivo
摘要:
sci-hub.se 参考文章(5)
Elisabeth Perzborn, Stefan Heitmeier, Volker Laux, Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction In Vitro and In Vivo Studies Journal of Cardiovascular Pharmacology and Therapeutics. ,vol. 20, pp. 554- 562 ,(2015) , 10.1177/1074248415578172
Thomas Eller, Jessica Busse, Marcus Dittrich, Tobias Flieder, Susanne Alban, Cornelius Knabbe, Ingvild Birschmann, Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests Clinical Chemistry and Laboratory Medicine. ,vol. 52, pp. 835- 844 ,(2014) , 10.1515/CCLM-2013-0936
Noa Zemer-Wassercug, Moti Haim, Dorit Leshem-Lev, Katia L. Orvin, Muthiah Vaduganathan, Ariel Gutstein, Ehud Kadmon, Aviv Mager, Ran Kornowski, Eli L. Lev, The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers Journal of Thrombosis and Thrombolysis. ,vol. 40, pp. 340- 346 ,(2015) , 10.1007/S11239-015-1245-Z
John Eikelboom, None, Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease The New England Journal of Medicine. ,vol. 377, pp. 1319- 1330 ,(2017) , 10.1056/NEJMOA1709118
Noel C. Chan, Jeffrey I. Weitz, Antithrombotic Agents: New Directions in Antithrombotic Therapy Circulation Research. ,vol. 124, pp. 426- 436 ,(2019) , 10.1161/CIRCRESAHA.118.313155